BR112013025633A2 - nanopartículas à base de lipídios - Google Patents

nanopartículas à base de lipídios

Info

Publication number
BR112013025633A2
BR112013025633A2 BR112013025633A BR112013025633A BR112013025633A2 BR 112013025633 A2 BR112013025633 A2 BR 112013025633A2 BR 112013025633 A BR112013025633 A BR 112013025633A BR 112013025633 A BR112013025633 A BR 112013025633A BR 112013025633 A2 BR112013025633 A2 BR 112013025633A2
Authority
BR
Brazil
Prior art keywords
lipid
compositions
based nanoparticles
amyloid
liposomal
Prior art date
Application number
BR112013025633A
Other languages
English (en)
Portuguese (pt)
Inventor
Annapragada Ananth
A Tanifum Eric
Dasgupta Indrani
L Eriksen Jason
c cook Stephen
Original Assignee
Alzeca Biosciences Llc
Board Of Regents Of The Univ Of Houston System
Univ Texas
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025633(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzeca Biosciences Llc, Board Of Regents Of The Univ Of Houston System, Univ Texas, Texas Childrens Hospital filed Critical Alzeca Biosciences Llc
Publication of BR112013025633A2 publication Critical patent/BR112013025633A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BR112013025633A 2011-04-06 2012-04-06 nanopartículas à base de lipídios BR112013025633A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (1)

Publication Number Publication Date
BR112013025633A2 true BR112013025633A2 (pt) 2017-08-08

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025633A BR112013025633A2 (pt) 2011-04-06 2012-04-06 nanopartículas à base de lipídios

Country Status (14)

Country Link
US (1) US9801957B2 (enExample)
EP (2) EP3366313A1 (enExample)
JP (3) JP6212032B2 (enExample)
KR (2) KR101973063B1 (enExample)
CN (1) CN104144708B (enExample)
AU (3) AU2012239888B9 (enExample)
BR (1) BR112013025633A2 (enExample)
CA (1) CA2831480C (enExample)
DK (1) DK2694116T3 (enExample)
ES (1) ES2685824T3 (enExample)
MX (1) MX357227B (enExample)
PL (1) PL2694116T3 (enExample)
PT (1) PT2694116T (enExample)
WO (1) WO2012139080A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2694116T3 (pl) 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
MX366972B (es) 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
AU2015330824A1 (en) * 2014-10-08 2017-05-25 Ananth Annapragada MRI imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
CN109414451B (zh) * 2016-05-16 2022-08-12 德克萨斯大学系统董事会 用于作为纳米粒递送tRNA的组合物及其使用方法
EP3548002B1 (en) 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
US11116854B2 (en) * 2020-01-29 2021-09-14 Texas Children's Hospital Targeted contrast agents for MRI of amyloid deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
KR20230012461A (ko) 2020-02-12 2023-01-26 텍사스 칠드런스 하스피탈 알파-시누클레인 침착의 mri를 위한 표적화된 조영제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
AU2076895A (en) 1994-03-28 1995-10-17 Daiichi Pharmaceutical Co., Ltd. Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
ATE287700T1 (de) * 1999-11-30 2005-02-15 Univ Arizona Strahlung-sensitive liposomen
AU2002211517A1 (en) * 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6821504B2 (en) * 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
US9943481B2 (en) * 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
EP2010223A2 (en) 2006-04-07 2009-01-07 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
WO2009015397A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
EP2217146A4 (en) 2007-12-05 2015-10-14 Marval Biosciences Inc NANOMETRIC SCALE CONTRAST AGENTS AND METHODS OF USE
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2410990A4 (en) 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
US8679531B2 (en) 2011-03-02 2014-03-25 Ananth Annapragada Vesicle compositions
PL2694116T3 (pl) 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
MX366972B (es) 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
AU2015330824A1 (en) 2014-10-08 2017-05-25 Ananth Annapragada MRI imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
KR20190031334A (ko) 2019-03-25
JP6212032B2 (ja) 2017-10-18
US9801957B2 (en) 2017-10-31
CN104144708B (zh) 2017-07-28
AU2017232156C1 (en) 2019-10-24
AU2012239888B9 (en) 2017-10-12
ES2685824T3 (es) 2018-10-11
KR20140074868A (ko) 2014-06-18
KR102035187B1 (ko) 2019-11-08
EP2694116B1 (en) 2018-06-13
AU2017232156B2 (en) 2019-07-11
US20120258044A1 (en) 2012-10-11
PT2694116T (pt) 2018-10-12
AU2019246775A1 (en) 2019-10-31
AU2017232156A1 (en) 2017-10-12
MX357227B (es) 2018-07-02
CN104144708A (zh) 2014-11-12
EP2694116A4 (en) 2015-06-03
JP2018035167A (ja) 2018-03-08
WO2012139080A3 (en) 2014-05-01
WO2012139080A2 (en) 2012-10-11
AU2012239888A1 (en) 2013-11-07
AU2012239888A2 (en) 2014-05-08
EP3366313A1 (en) 2018-08-29
JP2019151664A (ja) 2019-09-12
JP6533813B2 (ja) 2019-06-19
JP2014523854A (ja) 2014-09-18
KR101973063B1 (ko) 2019-04-30
AU2012239888B2 (en) 2017-06-22
MX2013011231A (es) 2015-03-05
DK2694116T3 (en) 2018-09-03
HK1203827A1 (en) 2015-11-06
CA2831480C (en) 2020-09-29
CA2831480A1 (en) 2012-10-11
PL2694116T3 (pl) 2018-12-31
EP2694116A2 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
BR112013025633A2 (pt) nanopartículas à base de lipídios
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112014004544A2 (pt) modificação com peg de nanopartículas com h-fosfonatos
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
BR112015014555A2 (pt) composições pesticidas e processos relacionados a isso
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
BR112014011594A2 (pt) anticorpos anti-il-36r
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
EA201270480A1 (ru) Новые соединения
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015000329A2 (pt) formulações de diclofenac
BR112014002758A2 (pt) composições para cuidados pessoais contendo zinco piritiona submetido à secagem
BR112013022052A2 (pt) ligantes antagonísticos de dr3
PH12018502580A1 (en) Formulations for paddy rice fields
BR112015009649A2 (pt) composto de triazolo
BR112015006705A2 (pt) antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático
BR112014000637A2 (pt) diagnóstico do mal de alzheimer
FR2991171B1 (fr) Procede de preparation d'une composition dermatologique comprenant des oleosomes
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
EP2709531A4 (en) NONINVASIVE LIVESTOCK DETERMINATION BY CREEPER DISPERSION

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements